Do You Need a Prescription for FORTIFY Blend? Is It Legal to Buy Online?

Federal law treats a drug as prescription-only when it is not safe for use except under the supervision of a licensed practitioner, including because of how it is used. A sterile solution of four peptides drawn into a syringe and injected under the skin meets that description. It may be dispensed only on a prescription, and the obligation sits with whoever dispenses it. That is the reason a grey market can exist at all: the seller, not the buyer, is the one who would need the prescription.

A new drug normally needs an approved application before it can be sold. Section 503A of the Federal Food, Drug, and Cosmetic Act exempts a drug compounded by a licensed pharmacy for an identified individual patient on a valid prescription. That exemption is the route every compounded peptide blend in the United States depends on. The prescription is not paperwork added to a sale; it is the legal event that makes the sale possible. The broader picture is in are peptides legal in the US and what is a 503A compounding pharmacy.

The FDA regulates the bulk substances a pharmacy compounds from, not the brand name of a blend. "FORTIFY" does not appear in any journal or on any FDA list. So the legal question for the vial is really four questions, one for each component, and the four answers are in three different places.

Thymosin alpha-1 was among the peptides placed in Category 2 in 2023. In September 2024 the FDA announced it would take thymosin alpha-1 to its Pharmacy Compounding Advisory Committee, and on 4 December 2024 that committee voted 4 in favour and 17 against adding both the free base and the acetate to the 503A Bulks List. The uses reviewed included hepatitis B and C, HIV, COVID-19, depressed vaccine response, several cancers and sepsis. A committee vote is a recommendation, not a rule: on the FDA's interim list updated 14 May 2026, thymosin alpha-1 appears in no category, and the FDA has not issued a final determination either way.

Both left Category 2 when the FDA announced, on 15 April 2026, the removal of twelve peptides from that category. On 23 July 2026 the advisory committee voted 8 to 6, with one abstention in each case, to recommend adding BPC-157 and KPV to the 503A Bulks List. The FDA's own scientists had recommended against inclusion, and the FDA's determination is still pending. Even a final listing would not make either one an FDA-approved drug: the bulks list governs what a pharmacy may compound from. The BPC-157 timeline in detail is in is BPC-157 banned.

Cathelicidin LL-37 was removed from Category 2 in the same April 2026 action. It was not reviewed at the July 2026 meeting; the FDA has said the committee will consider it at a meeting to be held before the end of February 2027. Removal from Category 2 lifts the safety-risk designation. It does not by itself place a substance on the positive list.

None of the four components is in Category 2 or otherwise restricted, and all four remain legal to prescribe and compound. Two have positive recommendations awaiting final FDA action, one has a negative recommendation the FDA has not acted on, and one is waiting for review. That makes FORTIFY lawful to prescribe, not FDA approved. A provider's menu can change when the FDA updates its lists and a pharmacy revises what it will compound.